文献速递头痛与眩晕

依瑞奴单抗治疗发作性偏头痛的一年持续疗效:STRIVE研究结果

One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study.
PubMed 文献 · Neurology · 2020-07-07

STRIVE研究纳入955例发作性偏头痛患者,双盲期随机接受安慰剂或依瑞奴单抗70/140mg每月皮下注射24周,随后845例再随机进入28周剂量盲法主动治疗期。52周时,两剂量组每月偏头痛天数较基线持续减少,≥50%应答率分别为61.0%和64.9%,安全性两剂量组相似。

要点

  • 依瑞奴单抗70/140mg治疗52周可持续减少发作性偏头痛患者每月偏头痛天数。
  • 52周时≥50%应答率70mg组61.0%、140mg组64.9%,≥75%和100%应答率也呈剂量相关趋势。
  • 双盲期≥50%应答者中86%在主动治疗期最后3个月维持≥50%应答。

核心结论

  • 依瑞奴单抗70mg或140mg每月皮下注射治疗发作性偏头痛52周可提供持续疗效,两剂量组安全性相似。

研究设计与样本

  • 随机、双盲、安慰剂对照的STRIVE研究,955例发作性偏头痛患者按1:1:1随机接受安慰剂或依瑞奴单抗70mg或140mg每月皮下注射24周。
  • 第24周时845例患者再随机(1:1)进入28周剂量盲法主动治疗期,接受依瑞奴单抗70mg或140mg。

主要发现

  • 双盲期基线平均每月偏头痛天数为8.3天。
  • 第52周时,较双盲期基线每月偏头痛天数平均变化(SE):70mg组-4.2(0.2)天,140mg组-4.6(0.2)天,与双盲期治疗分组无关。
  • 第52周时,70mg组≥50%、≥75%、100%减少每月偏头痛天数的患者比例分别为61.0%、38.5%、19.8%;140mg组分别为64.9%、40.8%、21.2%。
  • 双盲期依瑞奴单抗治疗且最后3个月≥50%应答并完成主动治疗期的患者中,86%在主动治疗期最后3个月维持≥50%应答。

关键数值与推荐

  • 第52周时,70mg组较双盲期基线每月偏头痛天数平均变化为-4.2(0.2)天,140mg组为-4.6(0.2)天。
  • 第52周时,70mg组≥50%、≥75%、100%应答率分别为61.0%、38.5%、19.8%;140mg组分别为64.9%、40.8%、21.2%。
  • 双盲期140mg转为主动治疗期70mg者,第24至52周每月偏头痛天数变化为-0.1(0.3)天;70mg转为140mg者为-1.8(0.3)天。

临床怎么用

  • 对于发作性偏头痛患者,可考虑使用依瑞奴单抗70mg或140mg每月皮下注射,治疗52周仍可维持减少每月偏头痛天数的效果。
  • 双盲期达到≥50%应答的患者在继续治疗时多数可维持应答,支持长期治疗策略。

局限性

  • 主动治疗期为剂量盲法而非双盲,可能影响安全性评价。
  • 研究仅纳入发作性偏头痛患者,结论不可外推至慢性偏头痛。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess efficacy and tolerability of 1-year erenumab treatment in patients with episodic migraine. METHODS: Patients were randomized (n = 955; 1:1:1) during the 24-week double-blind treatment phase (DBTP) to monthly subcutaneous placebo or erenumab 70 or 140 mg. At week 24, 845 patients were rerandomized (1:1) to erenumab 70 or 140 mg during the 28-week dose-blinded active-treatment phase (ATP). Monthly migraine days (MMD), achieving ≥50%, ≥75%, and 100% reduction in MMD, and safety/tolerability were assessed. RESULTS: Mean MMD at DBTP baseline was 8.3. At week 52, mean changes (SE) from pre-DBTP baseline/week 24 (pre-ATP baseline) in MMD were -4.2 (0.2)/-1.1 (0.2) (70 mg) and -4.6 (0.2)/-1.8 (0.2) (140 mg) irrespective of treatment during the DBTP. For patients reducing dose from 140 (DBTP) to 70 mg (ATP), change in MMD from week 24 to 52 was -0.1 (0.3), and for those increasing from 70 (DBTP) to 140 mg (ATP), -1.8 (0.3). At week 52, 61.0%, 38.5%, and 19.8% of patients on erenumab 70 mg, and 64.9%, 40.8%, and 21.2% on erenumab 140 mg, achieved ≥50%, ≥75%, and 100% reduction in MMD from DBTP baseline, respectively. Among erenumab-treated patients in DBTP who showed ≥50% reduction in MMD during the last 3 months of DBTP and completed ATP, 86% showed sustained responses at ≥50% during the last 3 months of ATP. Safety of erenumab in ATP was similar to DBTP; exposure-adjusted incidence rates of adverse events were similar for either dose. CONCLUSION: Over 52 weeks, erenumab provided sustained efficacy in episodic migraine; the safety profiles were similar between erenumab dose groups in the presence of dose blinding. CLINICALTRIALSGOV IDENTIFIER: NCT02456740. CLASSIFICATION OF EVIDENCE: Class II evidence that 52 weeks of treatment with erenumab 70 and 140 mg subcutaneously monthly results in sustained reductions in monthly migraine days and similar dose tolerability for patients with episodic migraine.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Goadsby PJ, Reuter U, Hallström Y, et al. One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study. Neurology. 2020. PMID: 32636324. doi:10.1212/WNL.0000000000010019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。